| abstract |
FIELD: chemistry of proteins, medicine, pharmacy. n SUBSTANCE: invention relates to sequences of the peptide-enhancer originating from different sequences of retrovirus envelope protein (gp41) that improve pharmacokinetic properties of any core polypeptide to which they are bound. Invention is based on discovery of the fact that hybrid polypeptides comprising sequences of the peptide-enhancer bound to the core polypeptide elicit the enhanced pharmacokinetic properties, such as the prolonged half-life time value. Invention relates also to a method for improving pharmacokinetic properties of any core polypeptide by addition of indicated sequences of the peptide-enhancer to indicated core polypeptide. Any pharmacologically acceptable peptides can be as core polypeptides that can be used, for example, as a therapeutic or prophylactic agent. The advantage of invention involves enhancing effectiveness of biologically active peptides in blood stream. n EFFECT: valuable properties of polypeptides. n 38 cl, 13 tbl, 17 dwg, 10 ex |